Boca Raton, FL -- (SBWIRE) -- 10/18/2013 -- StockFreak scours the market on a daily basis looking for the hottest penny stocks that may be the next big runners. StockFreak focuses on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks - pSivida Corp. (NASDAQ:PSDV), Real Goods Solar, Inc. (NASDAQ:RSOL), Endeavour Silver Corp. (CAN) (NYSE:EXK), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)
pSivida Corp. (NASDAQ:PSDV) ended lower -16.85% and complete the day at $3.80. The total number of shares changed hands during the day was 3.28 million. After opening at $4.39, the stock hit as high as $4.65. However, it traded between $1.17 and $5.60 over the last twelve months. pSivida Corp. develops products to deliver drugs and biologics primarily in the United States and the United Kingdom. The company, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back of the eye.
Has PSDV Found The Bottom and Ready To Move Up? Find Out Here
Real Goods Solar, Inc. (NASDAQ:RSOL) closed yesterday at $3.91, a +41.16% increase. Around 31.12 million shares were traded, beating an-average trading volume of 2.25 million shares. The company is now valued at around $118.19 million. Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction company in the United States. It provides commercial and residential solar energy solutions.
For How Long RSOL’s Gloss will Attract Investors? Find out via this report
Endeavour Silver Corp. (CAN) (NYSE:EXK) moved +9.09 percent higher at $4.20 and traded between $4.05 and $4.26 after opening the day at $4.07. Its performance over the last five days remained +2.69%, which stands at -2.55% for a month. Going back further than one month, 1-year performance after recent close was -46.77%. Endeavour Silver Corp. engages in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. It produces silver-gold from its underground mines.
For How Long EXK’s Gloss will Attract Investors? Find out via this report
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares rose, +11.39 percent to close at $4.50. The stock is down around -76.54% this year and -81.42% for the last 12 months. Around 19.51 million shares changed hands yesterday, higher from an-average trading volume of 1.02million shares. ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib).
Why Should Investors Buy ARIA After The Recent Gain? Just Go Here and Find Out
StockFreak scours the market on a daily basis looking for the hottest penny stocks that may be the next big runners. We strive to provide you with only the most opportunistic picks by pouring over mountains of data and charts. How often we send out our alerts is dependent on how often we find something worthwhile.
GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY THE FOLLOWING NOTICE AND DISCLAIMER MUST BE READ AND UNDERSTOOD AND YOU MUST AGREE TO THE TERMS CONTAINED THEREIN BEFORE USING THIS WEBSITE OR SUBSCRIBING TO OUR NEWSLETTER.
We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of StockFreak.com nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on StockFreak.com. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. StockFreak.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website.
StockFreak.com has been retained by an unrelated third party to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from such third party. Questions regarding this website may be sent to info@StockFreak.com.
Read Our Disclaimer at: http://www.stockfreak.com/disclaimer.html
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)